Short-Term Creatine Supplementation May Alleviate the Malnutrition-Inflammation Score and Lean Body Mass Loss in Hemodialysis Patients: A Pilot Randomized Placebo-Controlled Trial
Marini ACB, Motobu RD, Freitas ATV, Mota JF, Wall BT, Pichard C, Laviano A, Pimentel GD
JPEN. Journal of parenteral and enteral nutrition · 14 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2019-09-18 · JPEN J Parenter Enteral Nutr · vol. 44 · issue 5 · pp. 815–822
- Publisher
- Wiley
- Cited
- 74 citations · more than 70% of similar papers · 0.9× the field average
- References
- 28 works
- Access
- Open access (repository copy) · CC-BY
- Research areas
- Dialysis and Renal Disease Management · Nutrition and Health in Aging · Muscle metabolism and nutrition
- Keywords
- Creatine, Lean body mass, Medicine, Placebo, Randomized controlled trial, Internal medicine, Hemodialysis, Maltodextrin, Malnutrition, Creatine Monohydrate, Nutritional Supplementation, Gastroenterology, Endocrinology, Body weight, Chemistry
- MeSH
- muscle, skeletal, humans, malnutrition, inflammation, creatine, renal dialysis, pilot projects, double-blind method, body composition, quality of life, dietary supplements, adolescent, adult, middle aged, female, male, young adult
8 authors
From BR, GB, CH, IT
- Ana Clara B. MariniUniversidade Federal de Goiás
- Reika D. MotobuUniversidade Federal de Goiás
- Ana Tereza Vaz de Souza FreitasUniversidade Federal de Goiás
- João Felipe MotaUniversidade Federal de Goiás
- Benjamin Toby WallUniversity of Exeter
- Claude PichardUniversity Hospital of Geneva
Abstract
Background
Creatine supplementation has been proposed to alleviate muscle loss in various populations, but has not been investigated in hemodialysis (HD) patients. Thus, our objective was to evaluate whether creatine supplementation could attenuate the loss of lean body mass (LBM) and malnutrition-inflammation score (MIS) in HD patients.
Methods
A randomized, placebo-controlled, double blind, parallel-design study included HD patients, of both sexes, aged 18-59 years. The patients were allocated to a Placebo Group (PG; n = 15; received maltodextrin, 1st week: 40 g/day and 2nd-4th weeks: 10 g/day) and a Creatine Group (CG; n = 15; received creatine plus maltodextrin, 1st week: 20 g/day of creatine plus 20 g/day of maltodextrin and 2nd-4th weeks: 5 g/day of creatine plus 5 g/day of maltodextrin). Pre and post the intervention, patients were evaluated for food intake, MIS, body composition and biochemical parameters.
Results
CG group attenuated the MIS (Pre: 5.57 ± 0.72 vs. Post: 3.85 ± 0.47 score, P = 0.003) compared with PG (Pre: 5.71 ± 0.97 vs. Post: 5.36 ± 0.95 score, P = 0.317) (supplement × time P = 0.017, effect size: 0.964). The change of LBM was greater in CG than in PG (CG: Δ0.95 vs PG: Δ0.13 kg). At post-intervention, 28.6% of PG patients presented LBM loss and 71.4% remain stable. In contrast, 14.4% of CG patients had LBM loss, 42.8% remain stable and 42.8% gained. Food intake and quality of life did not change. CG increased the BMI and gait speed in post-compared to pre-moment, but no difference among the groups.
Conclusion
In HD patients, four weeks of creatine supplementation may alleviate the MIS as well as attenuate the LBM loss compared to placebo.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.